These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34865544)

  • 41. Who Will Pay for the COVID-19 Vaccines for Africa?
    Lucero-Prisno DE; Ogunkola IO; Imo UF; Adebisi YA
    Am J Trop Med Hyg; 2021 Jan; 104(3):794-796. PubMed ID: 33427194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective.
    McAdams D; McDade KK; Ogbuoji O; Johnson M; Dixit S; Yamey G
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33257418
    [No Abstract]   [Full Text] [Related]  

  • 43. COVID-19 Global Humanitarian Response Plan: An optimal distribution model for high-priority countries.
    Hezam IM
    ISA Trans; 2022 May; 124():1-20. PubMed ID: 33867131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Status of COVID-19 vaccine development.
    Taxt AM; Grødeland G; Lind A; Müller F
    Tidsskr Nor Laegeforen; 2020 Sep; 140(13):. PubMed ID: 32998488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic.
    Sharun K; Dhama K
    Arch Med Res; 2021 Oct; 52(7):761-763. PubMed ID: 33941393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Common Demand vs. Limited Supply-How to Serve the Global Fight against COVID-19 through Proper Supply of COVID-19 Vaccines.
    Su Y; Li Y; Liu Y
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162361
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
    Bilal M; Iqbal HMN
    Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Social Justice for Public Health: The COVID-19 Response in Portugal.
    Cordeiro-Rodrigues L
    J Bioeth Inq; 2020 Dec; 17(4):669-674. PubMed ID: 33169259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Justice through a Wide-Angle Lens.
    Haupt L
    Hastings Cent Rep; 2021 May; 51(3):2. PubMed ID: 34028821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Community Partnered Approach to Promoting COVID-19 Vaccine Equity.
    Scott T; Gutschow B; Ragavan MI; Ho K; Massart M; Ripper L; Muthama V; Miller E; Bey J; Abernathy RP
    Health Promot Pract; 2021 Nov; 22(6):758-760. PubMed ID: 34311592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positive Public Health Ethics: Toward Flourishing and Resilient Communities and Individuals.
    Prah Ruger J
    Am J Bioeth; 2020 Jul; 20(7):44-54. PubMed ID: 32485131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No-fault compensation schemes for COVID-19 vaccine injury: a mixed bag for claimants and citizens.
    Macleod S; Uberti F; Kameni E
    J Med Ethics; 2024 Jun; ():. PubMed ID: 38889950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Perspective on the Role of Point-of-Care "Immuno-Triaging" to Optimize COVID-19 Vaccination Distribution in a Time of Scarcity.
    Zhang Y; Rogers A; Nadeau K; Gu J; Yang S
    Front Public Health; 2021; 9():638316. PubMed ID: 34414149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Super-rapid race for saving lives by developing COVID-19 vaccines.
    Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A
    J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Destigmatizing public health concerns and supply of COVID-19 vaccines.
    Akel S; Bleibel F; Hale G; Khanfar NM
    Health Mark Q; 2021; 38(2-3):91-97. PubMed ID: 34420472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    Canaday DH; Gravenstein S
    Clin Infect Dis; 2021 Feb; 72(3):513-514. PubMed ID: 33527123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A public health framework for the equitable global allocation of vaccines: COVID-NEEDS.
    Jain V; Lorgelly P
    J Public Health Policy; 2022 Mar; 43(1):155-167. PubMed ID: 35022543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.